New biomaterials for the sustained release of nitric oxide: Past, present and future

Expert Opinion on Drug Delivery

Volumn 6, Issue 10, 2009, Pages 1113-1122

  Friedman, Adam ^a   Friedman, Joel ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Drug delivery; Nanotechnology; Nitric oxide; Sol gel

Indexed keywords

BIOMATERIAL; DIAZENIUMDIOLATE DERIVATIVE; DRUG VEHICLE; GLYCERYL TRINITRATE; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRITE; NITROPRUSSIDE SODIUM; S NITROSOGLUTATHIONE; S NITROSOTHIOL; TETRAETHOXYSILANE; TETRAMETHOXYSILANE; UNCLASSIFIED DRUG; ZEOLITE;

COMPOSITE MATERIAL; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TOLERANCE; HUMAN; HYDROGEL; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; REVIEW;

BIOCOMPATIBLE MATERIALS; HUMANS; NITRIC OXIDE; NITRIC OXIDE DONORS;

EID: 70349383201     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903196743     Document Type: Review

References (88)

1. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001;357:593-615 Excellent review on the physiologic generation and regulation of NO.
2. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994;78:915-918 (Pubitemid 24292319)
3. Weiner CP, Lizasoain I, Baylis SA, et al. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci 1994;91:5212-5216 (Pubitemid 24177823)
4. Schmidt HH, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta 1993;1178:153-175 (Pubitemid 23247995)
5. Shiva S, Gladwin MT. Shining a light on tissue NO stores: near infrared release of NO from nitrite and nitrosylated hemes. J Mol Cell Cardiol 2009;46(1):1-3. [Epub 17 October 2008]
6. Gladwin MT, Grubina R, Doyle MP. The new chemical biology of nitrite reactions with hemoglobin: R-state catalysis, oxidative denitrosylation, and nitrite reductase/anhydrase. Acc Chem Res 2009;42(1):157-167
7. Kaster MP, Rosa AO, Santos ARS, et al. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test. Int J Neuropsychopharmacol 2005;8:601-606 (Pubitemid 41400891)
8. Steiner AA, Antunes-Rodrigues J, McCann SM, etal. Antipyretic role of the NO-cGMP pathway in the anteroventral preoptic region of the rat brain. Am J Physiol Regul Integr Comp Physiol 2002;282:R584-93 (Pubitemid 34664611)
9. Gow AJ, Farkouh CR, Munson DA, et al. Biological significance of nitric oxide-mediated protein modifications. Am J Physiol Lung Cell Mol Physiol 2004;287:L262-8
10. Taylor EL, Megson IL, Haslett C, Rossi AG. Nitric oxide: a key regulator of myeloid inflammatory cell apoptosis. Cell Death Differ 2003;10:418-430 (Pubitemid 36626354)
11. Gaston B, Stamler JS. Biochemistry of nitric oxide. In: Fang FC, editor, Nitric oxide and infection; Springer US, NY. 1999. p. 37-55
12. Gladwin MT, Raat NJH, Shiva S, et al. Nitrite as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling, cytoprotection, and vasodilation. Am J Physiol Heart Circ Physiol 2006;291:H2026-35 (Pubitemid 44776623)
13. Smith I. Saving lives at what cost? RT Decis Makers Respir Care 2000:69-73
14. Yurtseven N, Karaca P, Kaplan M, et al. Effect of nitroglycerin inhalation on patients with pulmonary hypertension undergoing mitral valve replacement surgery. Anesthesiology 2003;99:855-858 (Pubitemid 37186075)
15. Goyal P, Kiran U, Chauhan S, et al. Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease. Br J Anaesth 2006;97:208-214 (Pubitemid 44295707)
16. Bennett BM, Leitman DC, Schroder H, etal. Relationship between biotransformation of glyceryl trinitrate and cyclic GMP accumulation in various cultured cell lines. J Pharmacol Exp Ther 1989;250:316-323 (Pubitemid 19195007)
17. Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis. Circulation 2002a;106:2510-2513
18. Gori T, Parker JD. The puzzle of nitrate tolerance: pieces smaller than we thought. Circulation 2002b;106:2404-8 These two papers [17,18] provide an excellent summary of the use of nitrates and the risk of tachyphylaxis. (Pubitemid 35244745)
19. Sage PR, de la Lande IS, Stafford I, et al. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation 2000;102:2810-2815 (Pubitemid 30954315)
20. Munzel T, Hink U, Yigit H, etal. Role of superoxide dismutase in invivo and invitro nitrate tolerance. Br J Pharmacol 1999;127:1224-1230 (Pubitemid 29326646)
21. Munzel T, Li H, Mollnau H, etal. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res 2000;86:E7-12
22. Munzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995;95:187-194
23. Ishikawa K, Kanamasa K, Ogawa I, et al. Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Jpn Circ J 1996;60:779-788 (Pubitemid 26389514)
24. Megson IL, Leslie SJ. LA-419, a nitric oxide donor for the treatment of cardiovascular disorders. Curr Opin Investig Drugs 2009;10(3):276-285
25. Grossi L, D'angelo S. Sodium nitroprusside: mechanism of NO release mediated by sulfhydryl-containing molecules. J Med Chem 2005;48:2622-2626 Important review describing the physicochemistry of SNP. (Pubitemid 40516451)
26. Bates JN, Baker MT, Guerra R, et al. Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem Pharmacol 1991;42(Suppl):S157-65
27. Butler AR, Glidewell C. Recent chemical studies of sodium nitroprusside relevant to its hypotensive action. Chem Soc Rev 1987;16:361-380
28. Megson IL. Nitric oxide donor drugs. Drugsof the Future 2000;25:701-715
29. Miller MR, Roseberry MJ, Mazzei FA, et al. Novel S-nitrosothiols do not engender vascular tolerance and remain effective in glyceryltrinitrate-tolerant rat femoral arteries. Eur J Pharmacol 2000;408:335-343 (Pubitemid 30821667)
30. Miller MR, Megson IL. Recent developments in nitric oxide donor drugs. Br J Pharmacol 2007;151(3):305-321 Megson's review of NO donors is thorough and explanatory.
31. Maragos CM, Morley D, Wink DA, et al. Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J Med Chem 1991;34:3242-3247
32. Hrabie JA, Klose JR, Wink DA, et al. New nitric oxide-releasing zwitterions derived from polyamines. J Org Chem 1993;58:1472-1476
33. Morley D, Keefer LK. Nitric oxide/nucleophile complexes: a unique class of nitric oxide-based vasodilators. J Cardiovasc Pharmacol 1993;22(Suppl 7):S3-9 (Pubitemid 23307815)
34. Kavdia M, Lewis RS. Nitric oxide delivery in stagnant systems via nitric oxide donors: a mathematical model. Chem Res Toxicol 2003;16:7-14 (Pubitemid 36139405)
35. Brilli RJ, Krafte-Jacobs B, Smith DJ, et al. Intratracheal instillation of a novel NO/nucleophile adduct selectively reduces pulmonary hypertension. J Appl Physiol 1997;83:1968-1975 (Pubitemid 28006498)
36. Shabani M, Simmon M, Smith DJ, et al. Transdermal delivery from nitric oxide-complexes (NONOates). FASEB J 2001;15:A146
37. Lam CF, Sviri S, Ilett KF, etal. Inhaled diazeniumdiolates (NONOates) as selective pulmonary vasodilators. Expert Opin Investig Drugs 2002;11:897-909
38. Maragos CM, Morley D, Wink DA, et al. Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J Med Chem 1991;34:3242-3247
39. Mowery KA, Schoenfisch MH, Saavedra JE, et al. Preparation and characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide release. Biomaterials 2000;21:9-21
40. Talukdar A, Wang PG. N-Nitroso compounds nitric oxide donors. In: Wang PG, Cai TB, Taniguchi N, editors. Wiley-VCH: Weinheim; 2005. p. 55-89
41. Saavedra JE, Billiar TR, Williams DL, et al. Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-induced apoptosis and toxicity in the liver. J Med Chem 1997;40:1947-1954
42. Saavedra JE, Booth MN, Hrabie JA, et al. Piperazine as a linker for incorporating the nitric oxide-releasing diazeniumdiolate group into other biomedically relevant functional molecules. J Org Chem 1999;64:5124-5131 (Pubitemid 29323701)
43. Dicks AP, Swift HR, Williams DLH, et al. Identification of Cu as the effective reagent in nitric oxide formation from S-nitrosothiols (RSNO). J Chem Soc-Perkin Trans 2 1996;(4):481-487
44. Holmes AJ, Williams DLH. Reaction of ascorbic acid with S-nitrosothiols: clear evidence for two distinct reaction pathways. J Chem Soc-Perkin Trans 2 2000;(8):1639-1644
45. Singh RJ, Hogg N, Joseph J, Kalyanaraman B. Mechanism of nitric oxide release from S-nitrosothiols. J Biol Chem 1996;271:18596-603 This is a descriptive review of the biochemistry of S-nitrosothiols. (Pubitemid 26322722)
46. Zai A, Rudd MA, Scribner AW, et al. Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. J Clin Invest 1999;103:393-399 (Pubitemid 29069989)
47. Megson IL, Webb DJ. Nitric oxide donor drugs: current status and future trends. Expert Opin Investig Drugs 2002;11:587-601 (Pubitemid 34520612)
48. Jourd'heuil D, Laroux FS, Miles AM, et al. Effect of superoxide dismutase on the stability of S-nitrosothiols. Arch Biochem Biophys 1999;361:323-330
49. Liu L, Hausladen A, Zeng M, et al. A metabolic enzyme for S-nitrosothiol conserved from bacteria to humans. Nature 2001;410:490-494 (Pubitemid 32240051)
50. Hanspal IS, Magid KS, Webb DJ, et al. The effect of oxidative stress on endothelium-dependent and nitric oxide donor-induced relaxation: implications for nitrate tolerance. Nitric Oxide 2002;6:263-270
51. Miller MR, Roseberry MJ, Mazzei FA, et al. Novel S-nitrosothiols do not engender vascular tolerance and remain effective in glyceryltrinitrate-tolerant rat femoral arteries. Eur J Pharmacol 2000;408:335-343 (Pubitemid 30821667)
52. Ramsay B, Radomski M, De Belder A, etal. Systemic effects of S-nitroso-glutathione in the human following intravenous infusion. Br J Clin Pharmacol 1995;40:101-102
53. Bryan NS, Rassaf T, Maloney RE, et al. Cellular targets and mechanisms of nitros(yl)ation: an insight into their nature and kinetics invivo. Proc Natl Acad Sci USA 2004;101:4308-13 This paper describes the general direction and potential of translating S-nitrosothiols to the bedside. (Pubitemid 38405925)
54. Kaposzta Z, Baskerville PA, Madge D, et al. L-arginine and S-nitrosoglutathione reduce embolization in humans. Circulation 2001;103:2371-2375 (Pubitemid 32448802)
55. Rauhala P, Andoh T, Chiueh CC. Neuroprotective properties of nitric oxide and S-nitrosoglutathione. Toxicol Appl Pharmacol 2005;207:91-95 (Pubitemid 41265501)
56. Gourine AV, Bulhak AA, Gonon AT, et al. Cardioprotective effect induced by brief exposure to nitric oxide before myocardial ischemia-reperfusion invivo. Nitric Oxide 2002;7:210-216
57. Vilahur G, Baldellou MI, Segales E, et al. Inhibition of thrombosis by a novel platelet selective S-nitrosothiol compound without hemodynamic side effects. Cardiovasc Res 2004;61:806-816 (Pubitemid 38249480)
58. Katsumi H, Nishikawa M, Yamashita F, et al. Development of polyethylene glycol-conjugated poly-S-nitrosated serum albumin, a novel S-Nitrosothiol for prolonged delivery of nitric oxide in the blood circulation invivo. J Pharmacol Exp Ther 2005;314:1117-1124 (Pubitemid 41205976)
59. Seabra AB, da Rocha LL, Eberlin LM, et al. Solid films of blended poly(vinyl alcohol)/poly(vinyl pyrrolidone) for topical S-nitrosoglutathione and nitric oxide release. J Pharm Sci 2005;94(5):994-1003
60. Al-Sa'doni HH, Khan IY, Poston L, et al. A novel family of S-nitrosothiols: chemical synthesis and biological actions. Nitric Oxide 2000;4:550-560 A good description of the biochemistry of this NO donor.
61. Seabra AB, Fitzpatrick A, Paul J, et al. Topically applied S-nitrosothiol-containing hydrogels as experimental and pharmacological nitric oxide donors in human skin. Br J Dermatol 2004;151:977-983 (Pubitemid 39573885)
62. Wheatley PS, Butler AR, Crane MS, et al. NO-releasing zeolites and their antithrombotic properties. J Am Chem Soc 2006;128:502-509
63. Frost MC, Meyerhoff ME. Synthesis, characterization, and controlled nitric oxide release from S-nitrosothiol-derivatized fumed silica polymer filler particles. J Biomed Mater Res A 2005;72:409-19 This project is a good example of a silica-based NO delivery system.
64. Mowbray M, Tan X, Wheatley PS, et al. Topically applied nitric oxide induces T-lymphocyte infiltration in human skin, but minimal inflammation. J Invest Dermatol 2008;128(2):352-360 This paper determines the importance of using NO delivery materials that are chemically inert in terms of inducing an inflammatory response.
65. Lunardi CN, da Silva RS, Bendhack LM. New nitric oxide donors based on ruthenium complexes. Braz J Med Biol Res 2009;42(1):87-93
66. Khan I, Dantsker D, Samuni U, et al. Beta 93 modified hemoglobin: kinetic and conformational consequences. Biochemistry 2001;40(25):7581-7592 (Pubitemid 32578023)
67. Khan I, Shannon CF, Dantsker D, et al. Sol-gel trapping of functional intermediates of hemoglobin: geminate and bimolecular recombination studies. Biochemistry 2000;39(51):16099-16109
68. Dunn B, Zink JI. Sol-gel chemistry. Acc Chem Res 200740(9):729 Excellent review of sol-gel chemistry and potential therapeutic applications.
69. Ellerby LM, Nishida CR, Nishida F, et al. Encapsulation of proteins in transparent porous silicate glasses prepared by the sol-gel method. Science 1992;255(5048):1113-1115
70. Lan EH, Dunn B, Zink JI. Nanostructured systems for biological materials. Methods Mol Biol 2005;300:53-79
71. Gupta R, Kumar A. Bioactive materials for biomedical applications using sol-gel technology. Biomed Mater 2008;3(3):034005 A broad review of the translational applications of sol-gel technology.
72. Kelm M, Schrader J. Nitric-oxide release from the isolated guinea-pig heart. Eur J Pharmacol 1988;155:317-321 (Pubitemid 18253627)
73. Mancinelli RL, McKay CP. Effects of nitric oxide and nitrogen dioxide on bacterial growth. Appl Environ Microbiol 1983;46:198-202
74. Shin JH, Schoenfisch MH. Improving the biocompatibility of invivo sensors via nitric oxide release. Analyst 2006;131:609-615
75. Hrabie JA, Klose JR, Wink DA, et al. New nitric oxide releasing zwitterions derived from polyamines. J Org Chem 1993;58:1472-1476
76. Nablo BJ, Chen T-Y, Schoenfisch MH. Sol-gel derived nitric oxide releasing materials that reduce bacterial adhesion. J Am Chem Soc 2001;123:9712-9713
77. Marxer SM, Rothrock AR, Nablo BJ, et al. Preparation of nitric oxide (NO)-releasing sol-gels. Chem Mater 2003;15:4193-4199
78. Nablo BJ, Schoenfisch MH. Antibacterial properties of nitric oxide-releasing sol-gels. J Biomed Mater Res A 2003;67:1276-1283
79. Nablo BJ, Prichard HL, Butler RD, et al. Inhibition of implant-associated infections via nitric oxide release. Biomaterials 2005;26:6984-6990 (Pubitemid 41095521)
80. Nablo BJ, Schoenfisch MH. Invitro cytotoxicity of nitric oxide-releasing sol-gel derived materials. Biomaterials 2005;26:4405-15 Interesting paper demonstrating the potential antimicrobial uses of NO-releasing materials
81. Robbins ME, Oh BK, Hopper ED, et al. Nitric oxide-releasing xerogel microarrays prepared with surface tailored poly(dimethylsiloxane) templates. Chem Mater 2005;17:3288-3296
82. Hetrick EM, Shin JH, Paul HS, et al. Antibiofilm efficacy of nitric oxide-releasing nanoparticles. Biomaterial 2009;30(14):2782-2789
83. Friedman A, Han G, Navati MH, et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 200819(1):12-20 This is personally an important paper as it describes/characterizes the platform for our NO-releasing sol-gel-based technology.
84. Shtelzer S, Rappoport S, Avnir D, et al. Properties of trypsin and of acid phosphatase immobilized in sol-gel glass matrices. Biotechnol Appl Biochem 1992;15(3):227-235
85. Navati MS, Friedman JM. Sugar-derived glasses support thermal and photo-initiated electron transfer processes over macroscopic distances. J Biol Chem 2006;281:36021-36028
86. Ray A, Friedman BA, Friedman JM. Trehalose glass-facilitated thermal reduction of metmyoglobin and methemoglobin. J Am Chem Soc 2002;124:7270-1 Initial description of the ability of sugar-glasses to facilitate the transfer of electrons, allowing for the thermal reduction scheme that ultimately generates nitric oxide in our platform. (Pubitemid 34670426)
87. Martinez L, Han G, Chacko M, et al. Antimicrobial and healing efficacy of sustained release nitric oxide nanoparticles against Staphylococcus aureus skin infections. J Invest Derm. Advance online publication, 23 April 2009
88. Davies K, Han G, Tar M, et al. Nanoparticles as a novel delivery for therapeutics targeting erectile dysfunction. #662: Newsworthy Abstract for the AUA 2009 Annual Meeting Press Program